NBIX Reiterated by Needham -- Price Target Maintained at $204

gurufocus.com · 2026-10-16

On October 12, 2023, analyst Ami Fadia reiterated a Buy rating on Neurocrine Biosciences (NBIX). The price target remains unchanged at $204.00, reflecting confi

TickrTrends take: Needham's maintained price target of $204 for NBIX suggests the analyst sees stable value in the company despite market movements. Against TickrTrends' current undervalued assessment for this Healthcare sector company, the reiteration indicates that analyst support remains consistent with longer-term value positioning. Investors focused on valuation metrics should monitor whether NBIX's fundamentals continue to support closure of any gap between current trading levels and the analyst's maintained target.

Read the full story at gurufocus.com →